Author(s): Dr Phoebe Star, Dermatology Registrar SA and NSW, Australia. Prof. Richard A. Scolyer, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia. Dr Pascale Guitera, Melanoma Institute Australia, The University of Sydney, Sydney; Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, Australia. Dr Kerry Crotty, Kossard Dermatopathologists. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. October 2018.
BAP1 (BRCA1-associated protein-1) is a nuclear protein encoded by the BAP1 tumour suppressor gene located on chromosome 3 (locus 3p21.1). The BAP1 protein acts as a deubiquitinating enzyme (removing the ubiquitin that regulates the degradation of proteins) and is involved in many key cellular functions including DNA repair, deubiquitination of histones, chromatin remodelling, transcription, and cell cycle regulation .
The prevalence of germline BAP1 mutations in the general population is not known. At least 215 affected individuals from 87 families have been reported in the literature to date (as of Sept 18) .
Germline BAP1 mutations are inherited in an autosomal dominant pattern. Each somatic cell of the affected offspring carries one mutant BAP1 allele and a normal wild type allele. An additional somatic mutation must be acquired in the wild type allele, in order for the cell to lose BAP1 tumour suppressor function.
The exact genotype-phenotype correlation between the location and type of mutation and cancer risk is not known . A number of mechanisms of mutagenesis have been reported, the majority of which result in a truncated protein .
Not all mutations are deleterious to protein function. Significant BAP1 mutations are those that affect either the nuclear localisation sequence, resulting in retention of the protein in the cytoplasm, or the ubiquitin carboxy-terminal hydrolase (UCH) catalytic domain, affecting deubiquitinating activity [2,5].
In 2011, an inherited cancer predisposition syndrome was proposed in association with the germline BAP1 mutation [6–8]. Carriers of the mutation have a high frequency of four main malignancies, including:
A wide range of other tumours have been reported in association with the mutation, including a higher incidence of:
Although it has a BRCA1 protein binding site, mutations in the BAP1 gene are not common in BRCA1-associated breast cancer. Further studies are needed for confirmation.
The lifetime risk of developing cancer in those with a harmful germline mutation is not known. Large population studies are required to estimate the true incidence of cancer in those with the mutation. In the 215 cases reported, 60 (28%) have developed uveal melanoma, 48 mesotheliomas (22%), 38 (18%) cutaneous melanoma, and 20 (9%) renal cell carcinoma . However, germline BAP1 mutations account for only a small proportion of these cancers overall; approximately 1.6% [8,9] to 4% [10,11] of uveal melanomas, 1–2%  of malignant mesothelioma, 0.01  to 0.63% [6,10] of cutaneous melanoma, and 1.2%  of renal cell carcinomas.
Cancer in BAP1 carriers is reported in a younger median age of onset and has varying prognostic significance compared with the general population (Table 1). Both somatic and germline BAP1 loss is associated with a more aggressive phenotype in uveal melanoma [9,15,16] and renal cell carcinoma [17,18], possibly shorter disease-free survival and melanoma-specific survival in cutaneous melanoma , but a better overall survival in mesothelioma [20–22].
The BAP1 inactivated melanocytic tumour is a rare kind of melanocytic naevus and is one of the earliest and most common clinical manifestations of the germline BAP1 mutation. The tumour is characterised by loss of BAP1 expression on immunoperoxidase staining. It was first described by Thomas Wiesner in 2011 . BAP1 inactivated melanocytic tumours occur in approximately 67–75% of germline BAP1 carriers, typically after the second decade of life [2,5]. They were initially histologically classified as atypical Spitz tumours because of the overlapping features between Spitz naevi and spitzoid melanoma, but at a molecular level, BAP1 loss and BRAF mutation are not seen in the majority of atypical Spitz tumours.
In the latest World Health Organisation (WHO) Classification of Skin Disease (4th Ed, 2018), the BAP1 inactivated melanocytic tumours are classified as BAP1-inactivated naevus and BAP1-inactivated melanocytoma (if there are atypical features) .
Other names include BAP-oma, Wiesner naevus, melanocytic BAP1-mutant atypical intradermal tumour (MBAIT), and naevoid melanoma-like melanocytic proliferation (NTEMP).
BAP1 inactivated melanocytic tumours may be sporadic in individuals without the BAP1 mutation or the germline BAP1 familial syndrome .
BAP1 inactivated melanocytic tumours appear from 2nd to 3rd decade of life. They are well circumscribed pink, orange, tan or skin-coloured papules, with an average size of 5 mm. Other features include:
The dermatoscopy of the BAP1 inactivated melanocytic tumour is not well described (case reports only).
A BAP1 inactivated melanocytic tumour is predominantly based in the dermis (Fig 1a), but it may be combined with a smaller adjacent junctional area that has more regular naevoid cells (which represents a common naevus component).
BAP1 inactivated melanocytic tumour is BAP1 negative (biallelic loss) and has BRAFV600E-mutant melanocytes. Note loss of BAP1 expression on immunohistochemistry (brown staining) of larger epithelioid melanocytes, while regular melanocytes retain BAP1 expression (fig 1d).
Figure 1: BAP1 deficient lesion. Male 14, back with pedunculated lesion. Images supplied by Professor Richard Scolyer.
There is very little known about the natural history of BAP1 inactivated melanocytic tumour or the phenotypic or histological features of primary cutaneous melanoma in this cohort. Despite a high lesion counts in patients with BAP1 inactivated melanocytic tumours, there is a low rate of cutaneous melanoma . Biallelic BAP1 loss and BRAF mutation is not sufficient for melanoma development . There have been some reports of transformation of a BAP1 inactivated melanocytic tumour to melanoma . Depending on the degree of atypia, lesions may be classified as having uncertain malignant potential. They typically have an indolent course .
There are no prescriptive guidelines in management of BAP1 inactivated melanocytic tumour. Any identified BAP1 inactivated melanocytic tumour should be closely followed with sequential digital dermatoscopic imaging and excised if change occurs. If they are excised, complete excision with histologically clear margins is mandatory. Consideration should be given to discussing lesions with uncertain malignant potential at a melanoma multidisciplinary meeting.
Indications for genetic screening include a strong personal or family history of the four main malignancies, coupled with multiple melanocytic naevi resembling BAP1 inactivated melanocytic tumours or epithelioid atypical tumours with spitzoid features on pathology [3,25].
Patients should be referred for genetic counselling prior to the decision to test for the genetic mutation. When referred for testing, the clinician should keep in mind that currently there are no formalised cancer surveillance plans for patients diagnosed as positive for the germline BAP1 mutation.
Testing for the mutation involves direct (Sanger) sequencing of blood or salivary DNA, and direct sequencing of tumour tissue. BAP1 inactivated melanocytic tumour tissue or other tumour tissue can be screened for loss of BAP1 nuclear staining on immunohistochemistry (IHC). IHC is highly sensitive and specific . However, there is a risk of false negatives. The loss of two BAP1 alleles is required for the test to show complete lack of BAP1 expression. Melanocytic naevi in germline BAP1-mutant individuals may not be BAP1 deficient on IHC staining as they retain one wild type allele. Cells with mono-allelic inactivation will have nuclear staining but may also show cytoplasmic staining for BAP1 if the nuclear localisation sequence is affected . The selection of a naevus looking like a BAP1 inactivated melanocytic tumour or a positive internal control may reduce this risk.
Note that BAP1-deficient naevi can be present in individuals without the germline mutation (due to somatic cause with two hits confined to tumour tissue). Formal genetic testing is always required to diagnose the germline mutation.
There are no formal or evidence-based cancer surveillance guidelines for patients with the germline BAP1 mutation. Current proposed surveillance recommendations include [1,3,5,20,28–30] screening for uveal melanoma, cutaneous melanoma, renal cell carcinoma, and mesothelioma.
A yearly review with an ophthalmologist specialising in uveal melanoma is recommended, starting at 16 years of age (a younger age may be considered if a family member has been diagnosed with early uveal melanoma). Some suggest starting screening at 11 years of age, which is 5 years younger than the earliest reported BAP1-associated uveal melanoma [3,28]. Six-monthly ophthalmic screening is recommended from 30 years old. Examination should consist of indirect ophthalmoscopy with a well dilated pupil, wide-field fundus photography, and ocular ultrasound.
Twice yearly full skin examination starting at 18 years of age should be undertaken by a dermatologist specialising in melanoma, involving systematic review of total body photography (TBP) from 18 years old. Sequential digital dermatoscopic examination or excision of any mildly irregular naevus or BAP1 inactivated melanocytic tumour-like lesion is recommended. Sun protection should also be emphasised.
Annual screening should begin between 30 and 55 years old with an abdominal and respiratory clinical examination, looking for abdominal mass, distention, ascites or signs of a pleural effusion.
The therapeutic benefit of drugs targeting different parts of the BAP1 pathway are under investigation for BAP1-mutant cancers. There are currently phase II and III clinical trials of the histone deacetalase inhibitor (HDACi) vorinostat, and the enhancer of zeste homolog 2 inhibitors (EZH2i, eg, tazemetostat) for patients with advanced pleural mesothelioma and metastatic uveal melanoma. Loss of BAP1 leads to abnormal ubiquitination of histone 2A (H2A) and over-expression of EZH2, which HDACi and EZH2i may counteract, respectively .
We would like to thank Clinical Geneticist, Dr Annabel Goodwin, Associate Professor R Max Conway, and Dr Rony Kapoor for their discussion about cancer incidence and surveillance issues in this cohort, and co-authorship on recent BAP1 surveillance proposal .
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.